Issue link: http://osercommunicationsgroup.uberflip.com/i/808986
Chain Drugstore Daily 1 9 Saturday, April 22, 2017 2017 Best of Show ADVANTAGE GROUP INTERNATIONAL DELIVERS FEEDBACK TO IMPROVE VENDOR PARTNER INTERACTION Advantage Group International is a third-party, unbiased, jointly-sponsored, annual benchmarking program that tar- gets the functions that matter most to improving business relationships between retailers and suppliers by help- ing each side see how they are perceived and how disconnects can be identified and corrected. Located in Chicago, Illinois, the company has been helping suppliers and retailers since 1988. The Advantage Report measures more than 20 practices that are relevant to strengthening all business practices. The company delivers a business tool to be used to evaluate performance rel- ative to competition and peers. The process is key to identifying strengths, weaknesses and opportunities to improve. Advantage's proven method- ology and processes delivers to more than 200 leading retailers worldwide, in more than 40 countries. Advantage Group International pro- vides reality checks and feedback oppor- tunities for both suppliers and retailers. For more than 500 retailers and suppliers around the world, the company helps clients improve business results with key trading partners. The data collected pro- vides Board level metrics at some of the largest CPG companies in the world. Strong performance in the Advantage study has been proven to correlate with strong financial performance for both retailers and suppliers in large drug chain stores, and their OTC and general mer- chandise suppliers. Advantage's 2016 study has shown that many companies experience a "reality check" regarding their retailers' ability to interact with suppliers and vice versa, but more importantly, the study shows compa- nies how to restructure and improve that interaction so it is more effective for all concerned. Patty Basche, Director, U.S. Client Services, noted, "You can't manage what you don't measure. Without benchmarking you don't have context on your performance. We measure the other half of the trading relationship – the 'how you do what you do' – across sales, marketing and supply chain. We share best-in-class advice from retailers and suppliers so their trading partners can raise their game and financial per- formance. We have thousands of indus- try professionals in the U.S. participating every year and 36,000-plus worldwide. Everything we do remains confiden- tial so individuals can provide 'the unvarnished truth' in their feedback without fear of reprisal. This breadth and depth gives our clients unparalleled insights into strengths, opportunities and improvement options. Our people are available to coach and guide cus- tomers through a wealth of insights so that they will be able to more effective- ly address specific business needs. We're not dumping data, we're collabo- rating with our clients, so they, in turn, can collaborate and drive better busi- ness results with their customers." For more information, visit www.advantag egroup.com or contact Patty Basche, Director, U.S. Client Services by calling 224.730.4198 or emailing pbasche @advantagegroup.com. PAR PHARMACEUTICAL: INNOVATIVE, COST-EFFECTIVE Since 1978, Par Pharmaceutical has been at the forefront of developing, manufacturing, marketing and distribut- ing safe, innovative and cost-effective pharmaceuticals that help improve patient quality of life. Every week in America, several million Par prescrip- tions are dispensed. In return for the trust that is placed in the company, it is committed to providing products of uncompromising quality. In fulfilling this mission, it delivers value to its cus- tomers and the physicians and patients that rely on it. In September 2015, Endo International PLC acquired Par Pharmaceutical, merging the business with Qualitest, thereby expanding the generics business to a top industry leader. Endo develops, manufactures, markets and distributes quality branded pharmaceutical and generic products through its operating companies. Endo has global headquarters in Dublin, Ireland and U.S. headquarters in Malvern, Pennsylvania. Today, Par Pharmaceutical's sales place it among the top four largest gener- ic pharmaceutical companies in the United States. Par conducts manufactur- ing in the United States and abroad, and markets and/or licenses more than 250 prescription drug product families. At Par, its most important resource is the talent and dedication of its more than 2,800 professionals in offices in Chestnut Ridge, New York; Irvine, California; Rochester, Michigan; Stratford, Connecticut; Chennai, India; Montebello, New York; London, England; and Huntsville Alabama. Each employee is part of a culture that values integrity, customer focus, teamwork, innovation and performance. Since the beginning of 2015, Par has acquired Ethics Bio Lab Pvt Ltd, an India-based contract research organiza- tion that conducts bioavailability, bioe- quivalence, pharmacokinetic and clinical endpoint studies, and Innoteq, Inc., a developer and manufacturer of innova- tive coated products, including orally dis- solving thin films and transdermal patch- es. Par possesses one of the most promis- ing new product pipelines in the generic drug industry, with more than 116 prod- ucts awaiting FDA approval, including almost 35 first to files, and more than 100 other products in development with continued focus on paragraph 4 and first to file opportunities. In recent years, the company has intro- duced generic versions of several major pharmaceutical products, including the following; Diclofenac Sodium Topical Gel 1% (Endo's Voltaren Gel ® ) Fluoxetine HCL Tablets 10mg and 20mg (Lilly's Prozac ® ), Quetiapine Fumarate ER Tablets 50mg,150mg, 200mg and 300mg (AstraZeneca's Seroquel XR ® ), Ezetimibe Tablets 10mg (Merck's Zetia ® ) and Dexmethylphenidate ER Capsules 25mg and 35mg (Novartis' Focalin XR ® ). Visit Par Pharmaceutical at booth #202. For more information, go to www.parpharm.com.